3136 results about "Methyl benzene" patented technology

The invention belongs to the technical field of a new chemical material, and in particular relates to a high-durability super-hydrophobic self-cleaning coating material and a preparation method thereof. The coating material of the invention is prepared by curing and drying nanoparticles with photo-catalytic activity, a low-surface-free-energy polymer and a cross-linking agent at the room temperature, wherein the low-surface-free-energy polymer consists of one or more of polysiloxane fluoride, dimethyl silicone polymer and polyphenylene methyl siloxane, which contain active groups, such as hydroxyl alkoxy group, carbon-carbon double bond, silanol group, siloxy group, and the like; the cross-linking agent is hydrogen-containing silicone oil or aminosilane; and the mass content of the photo-catalytic nanoparticles in the coating ranges from 10 to 60 percent. The coating is formed into a micro-nanostructure by nanoparticle self-organization; a super-hydrophobic self-cleaning coating with lotus effect is prepared from the coating and a cross-linked filming matrix with low surface energy; the persistence of a lotus-shaped super-hydrophobic characteristic of the coating is realized by using the photo-catalytic decomposition characteristic of an organic pollutant for the nanoparticles; and thus the material is suitable for large-area construction and has high weathering resistance andprominent self-cleaning characteristic.

A pharmaceutical composition comprises a drug-carrier system having a small-molecule drug of low water solubility, e.g. N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), and (+)-1-(5-tert-butyl-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102), in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The drug-carrier system, when mixed with an aqueous phase, typically forms a non-gelling, substantially non-transparent liquid dispersion. The composition is suitable for administration by a suitable route, e.g. orally, to a subject in need thereof.

The invention discloses a high temperature resistant heat-conducting silica gel sheet and a preparation method thereof. The high temperature resistant heat-conducting silica gel sheet is characterized by comprising the following components in parts by weight: 50-80 parts of vinyl end capped polydimethylsiloxane (PDMS), 20-50 parts of vinyl end capped methyl phenyl silicone oil, 0.3-10 parts of containing hydrogen silicone oil, 2-6 parts of platinum catalyst, 0.2-0.6 parts of inhibitor, 5-100 parts of heat resistant additive and 400-1200 parts of heat-conducting powder. The preparation method of the high temperature resistant heat-conducting silica gel sheet comprises the following steps: firstly, uniformly mixing the vinyl end capped polydimethylsiloxane and the vinyl end capped methyl phenyl silicone oil in a kneading machine; adding the treated or untreated heat-conducting powder and the heat resistant additive which are added in batches, after mixing uniformly, adding the containing hydrogen silicone oil, the inhibitor and the catalyst; and mixing uniformly, and heating and solidifying in a forming machine to form a sheet. The heat resistant silica gel sheet provided by the invention is aged at 250 DEG C for 1000 hours, but still has good usability, and the changes of the hardness and the heat conductivity coefficient are within acceptable ranges.

The present invention provides a compound represented by the formula (I):

wherein

• ring A is a ring which is optionally further substituted;
• R¹ is a hydrogen atom or a substituent;
• R² is a hydrogen atom or a substituent;
• R³ is a hydrogen atom or a substituent;
• R⁴ is a hydrogen atom or a substituent;
• R⁵ is a hydrogen atom or a substituent;
• R⁶ is a hydrogen atom or a substituent;
• X is ═N— or ═C(Z)- (Z is a hydrogen atom or a substituent);
• when X is ═C(Z)-, Z and R⁶ are optionally bonded to each other to form, together with the carbon atom bonded thereto, an optionally substituted ring,
• provided that when X is ═CH—, then R⁶ is not optionally substituted 2-piperidinyl, excluding N-imidazo[1,2-a]pyridin-2-yl-4-methyl-benzamide, N-imidazo[1,2-a]pyridin-2-yl-benzamide and N-(7-methylimidazo[1,2-a]pyridin-2-yl)-benzamide, or a salt thereof, and a pharmaceutical agent containing same.
• The compound of the present invention has an ASK1 inhibitory action, and is useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, inflammatory diseases and the like, and the like.

The invention belongs to the field of medicine, and in particular relates to a medical application of 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-((3-chloro-4-methylphenyl) amino)-4-oxobutanoate in a selective histone lysine-specific demethylase 1 (LSD1) inhibitor, especially the application in anti-tumor medicaments. Pharmacodynamic tests indicate that the 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-((3-chloro-4-methylphenyl) amino)-4-oxobutanoate has a remarkable LSD1 inhibiting effect, and has selectivity to homologous proteins MAO-A (monoamine oxidase-A) and MAO-B.

The invention concretely relates to a synthetic technology for pyraclostrobin. The synthetic technology comprises: firstly performing cyclization to obtain 1-(4-chlorophenyl)-pyrazol-3-one, oxidizing the pyrazol ring under the effect of an oxidant to generate 1-(4-chlorophenyl)-3-hydroxypyrazole, then using 2-nitrobenzyl bromide to performing etherification to generate 1-(4-chlorophenyl)-3-[2-(nitrophenyl)methoxy]-1H-pyrazole, then using a reducing agent to perform nitro reducing, so as to generate N-hydroxyl-2-[N'-(4-chlorophenyl)pyrazol-3'-yloxymethyl]aniline, then using ClCO2CH3 to perform N-acylation reaction to generate methyl N-hydroxyl-N-2-{[N'-(4-chlorophenyl)pyrazol-3'-yloxymethyl]phenyl}formate, and finally performing hydroxyl methylation under an alkaline condition to generate pyraclostrobin. The technology enables all operations in the pyraclostrobin preparation process to be relatively controllable, helps to improve the stability of the preparation process and improve the product yield, successfully employs low-cost reagents and substantially reduces production cost, and also the employed reagents are relatively small in toxicity, is relatively beneficial for environment protection, and has no corrosivity on plastic pipes, so that the production safety is improved.

The invention belongs to the technical field of chemical engineering, and discloses polyether modified organic silicone oil that adopts a comb structure shown in formula (1) and a preparation method and application as a defoamer, and overcomes the service restrictions of conventional organic silicone defoamers. The preparation method comprises the following steps: compounds such as short polyols polydimethyl siloxane or polymethyl phenyl siloxane in which end groups are hydrogen, allyl alcohol polyether, aliphatic esters or alkanes amides that contain end alkenyl are selected as raw materials to synthesize the polyether modified organic silicone oil. According to the invention, as a defoamer, the polyether modified organic silicone oil has good characteristics of self-emulsifying property, self-dispersing property, steady emulsifying property, good defoaming and foam inhibiting performance, high temperature resistance, and acid and alkali resistance.

A composition comprising (S)-5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylsulfinylpyrazole and (R)-5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylsulfinylpyrazole, enantiomerically enriched in the (S)-enantiomer.

A bactericidal preparation in the form of a solution, cream or ointment is disclosed. The preparation comprises a liquid compounded from photosynthesized hydrocarbons, isolates from hydrocarbons, 2-hydroxy-1-isopropyl-4-methyl-benzene (thymol) and butylated hydroxytoluene.

The invention discloses a method for preparing methyl phenyl hydrogen-containing silicone oil by rare earth super acid catalysis, which comprises the following steps of: taking methyl phenyl cyclosiloxane (DnMe, Ph, wherein n=3, 4, 5, 6), dimethyl cyclosiloxane (Dn, wherein n=3, 4, 5, 6), and methylhydrocyclosiloxane (DnH, wherein n=3, 4, 5, 6) as monomers; adding a blocking agent; and selecting rare earth super acids, controlling the reaction temperature, performing polymerization for a certain period under the protection of N2 gas, gradually raising the temperature to 205 DEG C under -0.9 MPa, and extracting low-boiling substances under reduced pressure to obtain the target product. The method has the advantages that: the catalyst can be separated only by filtering without washing neutralization, and the method has low labor intensity, simple process, simple and convenient operation and no pollution, and is convenient for industrialization. The product prepared by the method has good effects in the LED packaging process.

The invention discloses a preparation method of 2-(4-haloethyl) phenyl-2-methyl propionic ester and a synthesis method of bilastine, which comprises the following steps of: carrying out acylation reaction on 2, 2-dimethyl phenylacetate and halogen acetyl halides under the action of catalyst, to generate 2-(4-halogen acetyl) phenyl-2-methyl propionic ester; carrying out kishner-wolff-huang reduction reaction on the 2-(4-halogen acetyl) phenyl-2-methyl propionic ester, to reduce the carbonyl so as to generate the 2-(4-haloethyl) phenyl-2-methyl propionic ester; having condensation reaction with 1-ethoxy ethyl-2-pyridine-4-group benzimidazole by taking the 2-(4-haloethyl) phenyl-2-methyl propionic ester as a midbody to obtain esterified bilastine; and hydrolyzing, to generate the bilastine. The novel synthesis method of the bilastine provided by the invention can easily obtain raw materials, and is simple to operate, lower in cost, environment-friendly, and completely suitable for the industrial production.

A cooling topical cosmetic or dermatological preparation which comprises (1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)cyclohexane carboxamide and/or (1R,2S,5R)-N-(4-cyanomethyl-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide, in combination with menthoxypropanediol.

The invention discloses a polyurethane resin compound ink and preparation method thereof, comprising polyurethane resin, chloride-vinyl acetate resin, solvent, dye and dispersing auxiliary, wherein the solvent comprises methyl benzene, butanone, isopropyl alcohol. The composition of the polyurethane resin compound ink is: polyurethane resin liquor (30% solid content) 25-40%, chloride-vinyl acetate resin 0-4%, dye 5-25%, dispersing auxiliary 0.2-0.5%, methyl benzene 0-20%, butanone 25-35%, isopropyl alcohol 5-15%. The invention provides polyurethane resin compound ink with wide application range, good thermal stability, good adhesion and no aromatics solvent, in order to conquer the lacks such as not environment protection, narrow application range and bad thermal stability.

The invention discloses a method for the reaction of isoparaffin and olefin alkyl, which are catalyzed by acidic ionic liquid. The method adopts the isoparaffin and the C4 olefin as the reactant; the cation of the catalyst of the acidic ionic liquid is selected from imidazole cation or naphthyridine cation; the anion is selected from trifluoromethyl acid radical, methyl benzene acid radical or bicarbonate; the reaction solvent is water; the reaction temperature is 40 to 85 DEG C; the reaction pressure is 0 to 4.0 Mpa and the reaction time is 0.25 to 1 hours. The invention has the advantages of mild reaction condition, high activity, high selectivity, easy separation of oil and catalyst, circulating catalyst and low corrosive property.

A topical cosmetic and dermatological preparation for reducing skin reddening which comprises (1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)-cyclohexane carboxamide and/or (1R,2S,5R)—N-(4-cyanomethyl-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide.

Provided herein are processes for the preparation of (S)-(2R,3R,11bR-3-isobuty-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.

The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R¹, R², R^a, R^b, R^c, R^d, R^g, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.

A method of forming mixed xylenes from a heavy reformate using a dealkylation-transalkylation system includes the step of introducing both a heavy reformate containing methyl ethyl benzenes and tri-methyl benzenes and that is sufficiently free of toluene and a hydrogen-containing material into the dealkylation stage such that the heavy reformate and the hydrogen-containing material intermingle and contact the hydrodealkylation catalyst. The dealkylation-transalkylation system includes dealkylation, non-aromatic product gas separations and transalkylation stages. Toluene forms from the reaction of methyl ethyl benzenes and hydrogen in the presence of the hydrodealkylation catalyst. The method also includes the step of introducing a dealkylated heavy reformate into the transalkylation stage such that the dealkylated heavy reformate contacts a transalkylation catalyst, forming a transalkylation stage product mixture includes mixed xylenes.

The invention provides a group of polyhydroxy stilbene compounds, their preparing process and use for suppressing and eradicating SARS coronavirus. The preparing process comprises, preparing phosphonic ester by reacting multi-alkyl substituted chloro (bromo) methoxyl or pyridine compounds with triethyl phosphate, then reacting phosphonate ester compound with multi-alkyl (oxy) phenylpyridine methyl aldehyde to obtain multi-alkyl (oxy) stilbene compounds. Finally acting with boron tribromide to obtain polyhydroxy stilbene compounds with substituent groups.

The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.

The invention provides a preparation method and application of an anti-soil polymer. The prepared polymer is used as a dispersant for a hydraulic cementing agent and/or an aqueous dispersion for potential hydraulic cementing agent and has good anti-soil performance. The preparation method the anti-soil polymer comprises a step of subjecting polyether macromonomer A with a special structure, monomer B containing a phosphoric acid or phosphorous acid group, optional monomer D and aldehyde C to condensation polymerization so as to prepare the anti-soil polymer, wherein the monomer D is selected from the group consisting of phenol, aniline, p-/o-aminobezene solfonic acid, p-/o-hydroxybenzoic acid, p-/o-aminobenzoic acid, p-/o-hydroxyezene solfonic acid, p-/o-toluidine and p-/o-methylphenol, a mol ratio of the polyether macromonomer A to the monomer B to the monomer D is 1: (0.5-12): (0-8.0), and a mol ratio of the polyether macromonomer A to the monomer B and the monomer D is 1: (0.5-12.0).